Angptl2 Inhibitors

ANGPTL2 inhibitors pertain to a varied group of compounds that interact with ANGPTL2 or its related pathways, influencing its expression or function. These inhibitors are not a homogenous class of molecules but are rather characterized by their ability to affect the expression, regulation, or signaling pathways associated with ANGPTL2. They encompass a range of mechanisms, including activation of peroxisome proliferator-activated receptors (PPARs), modulation of lipid metabolism enzymes, and alteration of AMP-activated protein kinase (AMPK) activity. The compounds listed above include fibric acid derivatives such as fenofibrate, thiazolidinediones like pioglitazone, and statins that are primarily involved in lipid metabolism regulation. Compounds like metformin and rapamycin also appear in this list due to their influence on metabolic pathways that can indirectly modulate ANGPTL2 activity.

The actions of these compounds, although not directly inhibiting ANGPTL2, can lead to a decrease in its expression or a change in the activity of pathways that ANGPTL2 is involved in. For instance, fibrates and thiazolidinediones activate specific PPAR isoforms, which are known to regulate the expression of various genes, including ANGPTL2, thus contributing to altered ANGPTL2 levels. Similarly, statins, which target cholesterol biosynthesis, can incidentally influence ANGPTL2 gene expression. Metformin's activation of AMPK and rapamycin's inhibition of mTOR are further examples of how metabolic regulators can have downstream effects on ANGPTL2 signaling. The inclusion of natural compounds such as curcumin and omega-3 fatty acids highlights the diversity of molecules that can affect ANGPTL2-related pathways, predominantly through anti-inflammatory effects and the modulation of lipid profiles, respectively.